(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Monday reported interim results from the ongoing Phase 2 COURAGE study evaluating semaglutide and trevogrumab with or without garetosmab for the ...

Regeneron’s strategy relies on two experimental lab-made antibodies, trevogrumab and garetosmab. Both antibodies are linked to separate proteins that play key roles in limiting skeletal muscle ...

The dozen new drugs, including those furthest along in development from Eli Lilly, Regeneron, Scholar Rock and Veru, target proteins tied to muscle preservation or growth.

Study Overview: Bayer AG and Regeneron Pharmaceuticals are conducting a Phase 4 study titled An Open-label, Non-randomized, Multi-center, Phase 4 Pharmacokinetic Study to Evaluate the Systemic ...

Regeneron has promising muscle preservation in obesity treatment, "Trevogrumab," in phase two. Libtayo is Regeneron's PD-1 inhibitor approved for certain skin cancers and is under investigation ...

Triple combo therapy cut 30 pounds with just 2 lbs of lean mass lost, showing strong fat-targeting results in the midstage trial. Regeneron inks $80 million deal with Hansoh for Phase 3 obesity ...